Literature DB >> 20691591

Predictors of malignancy in screen-detected breast masses with indeterminate/equivocal (grade 3) imaging features.

Gelareh Farshid1, Adrienne Walker, Glenda Battersby, Thomas Sullivan, P Grantley Gill, Steve Pieterse, Peter Downey.   

Abstract

BACKGROUND: The mammographic grading system used by BreastScreen Australia accredited programs requires needle biopsy of lesions with indeterminate features (grade 3). We wished to determine the predictors of malignancy for these common lesions, so as to reduce surgery for benign lesions.
DESIGN: Grade 3 masses assessed between Jan 1996-Dec 2005 are included. New or changing lesions were identified through film review. Imaging, demographic and final outcome data were tabulated. Statistical analysis was performed to determine the predictors of malignancy.
RESULTS: 1181 lesions, including 623 new or changing masses are assessed. Of these 98 (8.3%) were malignant. Malignancy was found in 3% first round masses versus 13% of new or changing lesions. Withholding needle biopsy results, interval change (OR 2.85, p = 0.0001), increasing age (p = 0.0001) and diameter were independent predictors of malignancy, lesion diameter having an inverse relationship with malignancy. Once needle biopsy results were included, this parameter became the sole predictor of malignancy as other factors lost significance in a multivariate model.
CONCLUSION: Surgical biopsy is not indicated in well-sampled grade 3 masses with benign needle biopsy results. Surgery is valuable for diagnosis or treatment of the remaining such masses without benign needle biopsy results. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20691591     DOI: 10.1016/j.breast.2010.07.002

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  1 in total

1.  Reducing Unnecessary Biopsies Using Digital Breast Tomosynthesis and Ultrasound in Dense and Nondense Breasts.

Authors:  Ibrahim Hadadi; Jillian Clarke; William Rae; Mark McEntee; Wendy Vincent; Ernest Ekpo
Journal:  Curr Oncol       Date:  2022-08-04       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.